The blood-based analysis of circulating tumor cells or tumor derived nucleic acids is referred to as “liquid biopsy”. The main target of this analysis is cell-free DNA (cfDNA), which is released into the blood stream by necrotic and apoptotic cells. Elevated levels of cfDNA are found in patients with cancer and other types of diseases.
Since only a small fraction of the circulating DNA is derived from the tumor (ctDNA), highly sensitive detection methods, as for example digital droplet PCR (ddPCR), or next generation sequencing (NGS), are advantageous.
The applications of liquid biopsy are manifold, therefore, our liquid biopsy product portfolio covers the targeted analysis of single variants, a selected panel of cancer associated genes, as well as large, explorative approaches.
CeGaT’s sequencing and digital PCR services offer reliable and accurate insights into liquid biopsies, from nucleic acid extraction to tailored data analysis.
Your project will benefit from our long-standing expertise in the diagnostic field and thus, strict quality standards, as well as practical knowledge.
Application areas of Liquid Biopsies:
- Monitoring a tumor disease
- Monitoring treatment response
- Patient stratification, treatment selection
- Detection of minimal residual disease
- Early detection and profiling of resistance to therapy